SafeOp Surgical, Inc. (“SafeOp”) has received FDA clearance to market its Evoked Potential Assessment Device (EPAD™). The device is portable and intended for use in monitoring neurological status by recording somatosensory evoked potentials (SSEPs) or assessing the neuromuscular junction (NMJ).

LivHOME, Inc., one of the nation’s largest providers of professionally led at-home care for seniors, announced today that it has appointed Richard (Rick) Slager to its Board of Directors. Slager will focus on seeking new opportunities for LivHOME to grow and develop as it continues bringing top quality care to seniors living at home.

Medical device manufacturer Vidacare Corporation of San Antonio, Texas has entered into a merger agreement to be acquired by Teleflex Incorporated (NYSE: TFX) for $262.5 million plus Vidacare's net cash.

Vidacare Corporation has increased its sales force by approximately 30 percent to support international commercialization of the company’s products directly through to the end user. The company has hired over 20 sales professionals to represent Vidacare product systems, including the EZ-IO Intraosseous Vascular Access System and the OnControl Bone Marrow and Bone Access Systems, in targeted international markets.

Vidacare Corporation has launched a free point-of-care app for health care professionals to answer clinical and training questions related to its EZ-IO® Intraosseous Vascular Access System. The app is now available for download at the Apple iTunes Store and features interactive guides, videos and instructions on using the EZ-IO to obtain intraosseous vascular access.

The EZ-IO® Intraosseous Vascular Access System by San Antonio-based Vidacare Corporation was featured in the premiere of the National Geographic Channel’s six-part documentary miniseries Inside Combat Rescue on February 18.

LEXINGTON, Mass., January 9, 2013 -- Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the closing of a $118 million underwritten public offering of 2,472,500 shares of common stock, including 322,500 shares of common stock which were issued pursuant to the exercise of the underwriters’ option to purchase additional shares, at a price of $47.53 per share.

LOS ANGELES--(BUSINESS WIRE)-- LivHOME CareMonitor™ (www.livhomecaremonitor.com), a remote care service first announced in March, is beginning to roll out nationwide where LivHOME services are offered. It is currently available in Los Angeles, Walnut Creek and Riverside, Calif., and will continue to be rolled out to additional markets in late 2012 and early 2013. LivHOME CareMonitor™ is provided by LivHOME, Inc., one of the nation’s largest providers of professionally led at-home care for seniors.

Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare diseases, today announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase (LAL) Deficiency at the American Association for the Study of Liver Diseases (AASLD) annual meeting being held in Boston, MA, November 9-13, 2012.

The Wall Street Journal announced the winners of its 2012 Technology Innovation Awards today, and for the second time, Vidacare Corporation has been recognized for its ground-breaking technology. Vidacare’s OnControl Bone Marrow System is the overall Bronze winner in this year’s Technology Innovation Awards and the winner of the Medical Devices category. Vidacare’s EZ-IO Intraosseous Infusion System won the overall Gold Technology Innovation of the Year award from the same program in 2008.

On the heels of a recent expanded FDA indication to allow for “bone biopsy of the vertebral body and bone lesions,” Vidacare Corporation’s OnControl Bone Access System has developed a new extension of its technology platform. The OnControl Bone Access System Coaxial Biopsy Tray for powered bone biopsy provides a tool for clinicians to access hard bones and perform biopsies of bone lesions using the company's innovative power-driver and specially engineered needle.

TULLIS HEALTH INVESTORS INC.

The firm was founded in 1986 by Jim Tullis, a leading health care investment banker and 14-time Institutional Investor All-Star. Under his leadership, the Tullis family of funds has been investing successfully and exclusively in privately held health care companies through several funds for over 30 years. Considered a pioneer in healthcare focused venture and growth capital, the team invests in all major areas of the healthcare industry. US-based, with an office in North Palm Beach, Florida, the firm also has international operations including a presence in Beijing. The team combines extensive operating and clinical experience in the US and globally, with a strong history of successful health care private equity investing.

Investment Approach

Tullis provides equity and equity-related capital to small and emerging health care companies.Tullis focuses on companies that have already established operations or have completed a substantial portion of their development process for new products, technologies and services. Many Tullis companies have generated meaningful revenue and require capital in order to reach value-enhancing milestones in a defined two- to four-year period. Others are research and development stage medical companies which have passed key milestones, but require additional capital to achieve commercial status.